hematology

Dr. Shaji K Kumar, Associate Professor of Hematology and Medicine at Mayo Clinic in Rochester, MN, discusses updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines (direct link available at http://tiny.cc/V2dk9 or visit journal at www.mayoclinicproceedings.com). The identification of well-defined and reproducible prognostic factors and introduction of new therapies with unique modes of action and impact on disease outcome have for the first time opened...

Dr. Ayalew Tefferi, Professor of Hematology and Medicine at Mayo Clinic in Rochester, MN, discusses the findings of the largest ever study with the most mature data currently available of patients with primary myelofibrosis younger than 60 years. These 176 patients were followed up for a median of 8 years or until death. Improvement in survival was noted in those with high- and moderate-risk disease but not in those with low-risk disease. These findings suggest a salutary effect of recent...

Dr. S. Vincent Rajkumar, Mayo Clinic hematologist, discusses the first systematic study (published in August issue of Mayo Clinic Proceedings available at http://tinyurl.com/lr55lc) to determine association of Monoclonal Gammopathy of Undetermined Significance (MGUS) with all diseases in 17,398 patients.